Non-Current Liabilities
Operating Lease Liability Payments - 2026 (Lessee)
Neurocrine Biosciences Operating Lease Liability Payments - 2026 (Lessee) decreased by 0.7% to $59.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 1.5%, from $60.70M to $59.80M. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Liabilities
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ2 2020
Last reportedQ1 2026May 5, 2026
How to read this metric
Allows for precise modeling of fixed costs in the specified future period.
Detailed definition
The specific cash outflows contractually obligated for operating leases during the calendar year 2026. This provides a s...
Peer comparison
Standard disclosure for specific future year lease obligations.
Metric ID:
lease_liability_payments_2026_lesseeHistorical Data
15 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $17.00M | $17.00M | $15.90M | $15.90M | $15.90M | $15.70M | $15.70M | $15.70M | $34.80M | $35.80M | $35.80M | $60.70M | $60.70M | $60.20M | $59.80M |
| QoQ Change | — | +0.0% | -6.5% | +0.0% | +0.0% | -1.3% | +0.0% | +0.0% | +121.7% | +2.9% | +0.0% | +69.6% | +0.0% | -0.8% | -0.7% |
| YoY Change | — | — | — | -6.5% | -6.5% | -1.3% | -1.3% | -1.3% | +121.7% | +128.0% | +128.0% | +74.4% | +69.6% | +68.2% | -1.5% |
Range$15.70M – $60.70M
CAGR+43.2%
Avg YoY Growth+47.6%
Median YoY Growth+33.4%
Current Streak2 quarters decline
Operating Lease Liability Payments - 2026 (Lessee) at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's operating lease liability payments - 2026 (lessee)?
- Neurocrine Biosciences (NBIX) reported operating lease liability payments - 2026 (lessee) of $59.80M in Q1 2026.
- How has Neurocrine Biosciences's operating lease liability payments - 2026 (lessee) changed year-over-year?
- Neurocrine Biosciences's operating lease liability payments - 2026 (lessee) decreased by 1.5% year-over-year, from $60.70M to $59.80M.
- What does operating lease liability payments - 2026 (lessee) mean?
- The amount of operating lease payments due in the year 2026.